Suhaib Shalan

Suhaib Shalan

Auto-generated profile, based on publicly available information

Suhaib Shalan

Faculty of Medicine, The Hashemite University, Zarqa, Jordan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
OSOthman Mohammad Saleh
Othman Mohammad Saleh
KAKhaled Albakri
Khaled Albakri
AAAbdalrahmn Altiti
Abdalrahmn Altiti
IAIser Abutair
Iser Abutair
SSSuhaib Shalan
Suhaib Shalan
MKMohammad A. Kamal
Mohammad A. Kamal
Long non-coding RNAs (IncRNAs) are regulatory RNA transcripts that have recently been associated with the onset of many neurodegenerative illnesses, including Alzheimer's disease (AD). Several IncRNAs have been found to be associated with AD pathophysiology, each with a distinct mechanism. In this review, we focused on the role of IncRNAs in the pathogenesis of AD and their potential as novel biomarkers and therapeutic targets. Searching for relevant articles was done using the PubMed and Cochrane library databases. Studies had to be published in full text in English in order to be considered. Some IncRNAs were found to be upregulated, while others were downregulated. Dysregulation of IncRNAs expression may contribute to AD pathogenesis. Their effects manifest as the synthesis of beta-amyloid (Aβ) plaques increases, thereby altering neuronal plasticity, inducing inflammation, and promoting apoptosis. Despite the need for more investigations, IncRNAs could potentially increase the sensitivity of early detection of AD. Until now, there has been no effective treatment for AD. Hence, InRNAs are promising molecules and may serve as potential therapeutic targets. Although several dysregulated AD-associated lncRNAs have been discovered, the functional characterization of most lncRNAs is still lacking.